Migraine treatment, Ubrelvy, receives FDA approval
by Press Release from Outbreak News Today on (#4X02N)
The U.S. Food and Drug Administration today approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Ubrelvy is not indicated for the preventive treatment of migraine. It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists ["]
The post Migraine treatment, Ubrelvy, receives FDA approval appeared first on Outbreak News Today.